ETTX Key Statistics, Chart & Performance
The current stock price of ETTX is 2.19 null. In the past year, price decreased by -12.05%.
ETTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ETTX. When comparing the yearly performance of all stocks, ETTX is one of the better performing stocks in the market, outperforming 90.67% of all stocks.
ETTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ETTX. Both the profitability and financial health of ETTX have multiple concerns.
ETTX Financial Highlights
Over the last trailing twelve months ETTX reported a non-GAAP Earnings per Share(EPS) of -1.12. The EPS increased by 28.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -117.26% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ETTX Forecast & Estimates
8 analysts have analysed ETTX and the average price target is 2.04 null. This implies a price decrease of -6.85% is expected in the next year compared to the current price of 2.19.
ETTX Ownership
About ETTX
Company Profile
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-09-26. The firm is focused on the discovery, development, and commercialization of targeted antibacterial products that address unmet medical needs to treat infections caused by multidrug-resistant pathogens. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), which is an intravenous, combination of sulbactam, an IV b-lactam antibiotic, and durlobactam, a novel broad-spectrum IV b -lactamase inhibitor (BLI) for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Its second late-stage product candidate is zoliflodacin, which is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. Its third product candidate is ETX0282CPDP for the oral treatment of urinary tract infections. ETX0282CPDP is a combination of ETX0282, a novel oral BLI, with cefpodoxime proxetil (cefpodoxime), an oral b-lactam antibiotic.
Company Info
Entasis Therapeutics Holdings Inc
35 Gatehouse Drive
Waltham MASSACHUSETTS 02451 US
CEO: Manoussos Perros
Employees: 51
Phone: 17818100120.0
Entasis Therapeutics Holdings Inc / ETTX FAQ
What does Entasis Therapeutics Holdings Inc do?
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-09-26. The firm is focused on the discovery, development, and commercialization of targeted antibacterial products that address unmet medical needs to treat infections caused by multidrug-resistant pathogens. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), which is an intravenous, combination of sulbactam, an IV b-lactam antibiotic, and durlobactam, a novel broad-spectrum IV b -lactamase inhibitor (BLI) for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Its second late-stage product candidate is zoliflodacin, which is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. Its third product candidate is ETX0282CPDP for the oral treatment of urinary tract infections. ETX0282CPDP is a combination of ETX0282, a novel oral BLI, with cefpodoxime proxetil (cefpodoxime), an oral b-lactam antibiotic.
Can you provide the latest stock price for Entasis Therapeutics Holdings Inc?
The current stock price of ETTX is 2.19 null. The price decreased by -0.45% in the last trading session.
What is the dividend status of Entasis Therapeutics Holdings Inc?
ETTX does not pay a dividend.
What is the ChartMill rating of Entasis Therapeutics Holdings Inc stock?
ETTX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for ETTX stock?
8 analysts have analysed ETTX and the average price target is 2.04 null. This implies a price decrease of -6.85% is expected in the next year compared to the current price of 2.19.
What is the employee count for ETTX stock?
Entasis Therapeutics Holdings Inc (ETTX) currently has 51 employees.
What is the next earnings date for ETTX stock?
Entasis Therapeutics Holdings Inc (ETTX) will report earnings on 2022-08-09.